octanate is used to treat hemophilia type A by replacing the deficiency of clotting factor VIII in the blood. This helps stop and control bleeding, reduces the risk of recurrent bleeding episodes, and contributes to preventing bleeding complications and stabilizing the patient's condition when used regularly under medical supervision.
It also helps improve the quality of life for hemophilia patients by reducing spontaneous bleeding and protecting joints from damage caused by recurrent bleeding. Furthermore, it supports mobility and allows for safer and more stable participation in daily activities when the treatment plan is followed.